Biogen Names Priya Singhal as Executive Vice President, Head of Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Biogen (BIIB) gains ahead of lecanemab PDUFA
January 6, 2023 7:05 AM ESTBiogen (NASDAQ: BIIB) is gaining 1% in pre-open trade ahead of lecanemab's accelerated approval PDUFA today.
After the close, analysts at RBC Capital noted that Eisai's patient assistance hotline for Leqembi/lecanemab just became active suggesting "increased likelihood an approval."
... MoreRBC Capital on Biogen (BIIB): 'a very favorable stock setup'
January 5, 2023 4:11 PM ESTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Sometime between late this morning and now, Eisai's patient assistance hotline for Leqembi/lecanemab just became active, whereas for the last several weeks the phone number (which we obtained via Google search) had not been... More
Biogen's (BIIB) accelerated PDUFA lecanemab approval the likely outcome claim analysts
January 5, 2023 11:50 AM ESTBiogen's (NASDAQ: BIIB) lecanemab's accelerated approval PDUFA is slated for Friday, January 6, and analysts have been weighing in with their view heading into the date.
Jefferies analyst Michael Yee, who has a Buy rating and a $350 price target on Biogen shares, said in a note to clients that the "consensus assumes clean approval, which is reasonable though mostly... More
